bioAffinity Technologies (BIAF) Cost of Revenue (2022 - 2025)

bioAffinity Technologies has disclosed Cost of Revenue across 4 years of filings, most recently posting $900126.0 for Q4 2025.

• In Q4 2025, Cost of Revenue fell 42.38% year-over-year to $900126.0; the TTM figure through Dec 2025 stood at $4.2 million (down 29.36% YoY), while the FY2025 annual figure was $4.2 million, down 29.36% from the prior year.
• Cost of Revenue eased to $900126.0 in Q4 2025, from $942211.0 in the prior quarter.
• Over the last five years, Cost of Revenue for BIAF reached as high as $1.7 million in Q4 2023 and fell as low as $87.0 in Q1 2023.
• The 4-year median for Cost of Revenue is $942211.0 (2025), against an average of $796775.0.
• Annual changes were most pronounced in 2024 — Cost of Revenue surged 1808452.87% — and 2025, when it sank 42.38%.
• A 4-year view of Cost of Revenue shows it stood at $175.0 in 2022, then surged by 951248.0% to $1.7 million in 2023, then declined by 6.17% to $1.6 million in 2024, then slumped by 42.38% to $900126.0 in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $900126.0, $942211.0, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.